ZORN LUDWIG
No ORCID on file
· 143 papers in corpus
· active 2004-2011
Frequent coauthors
- KRUEGER MARTIN 130
- MENRAD ANDREAS 130
- HESS-STUMPP HOLGER 130
- HABEREY Martin 130
- HUTH ANDREAS 130
- INCE STUART 117
- THIERAUCH KARL-HEINZ 91
- THIERAUCH KARL HEINZ 39
- INCE STUAT 26
- WINTERMANTEL TIM 13
2011
The invention relates to selective estrogen receptor modulators (SERMs) and to processes for production thereof, to the use thereof for treatment and/or prophylaxis of disorders, and to the use thereof for production of medicaments for trea…
2011
The invention relates to selective estrogen receptor modulators (SERMs) and to processes for production thereof, to the use thereof for treatment and/or prophylaxis of disorders, and to the use thereof for production of medicaments for trea…
2011
The invention relates to selective estrogen receptor modulators (SERMs) and to processes for production thereof, to the use thereof for treatment and/or prophylaxis of disorders, and to the use thereof for production of medicaments for trea…
2011
The invention relates to selective estrogen receptor modulators (SERMs) and to processes for production thereof, to the use thereof for treatment and/or prophylaxis of disorders, and to the use thereof for production of medicaments for trea…
2011
The invention relates to selective estrogen receptor modulators (SERMs) and to processes for production thereof, to the use thereof for treatment and/or prophylaxis of disorders, and to the use thereof for production of medicaments for trea…
2011
The invention relates to selective estrogen receptor modulators (SERMs) and to processes for production thereof, to the use thereof for treatment and/or prophylaxis of disorders, and to the use thereof for production of medicaments for trea…
2011
The invention relates to selective estrogen receptor modulators (SERMs) and to processes for production thereof, to the use thereof for treatment and/or prophylaxis of disorders, and to the use thereof for production of medicaments for trea…
2011
The invention relates to selective estrogen receptor modulators (SERMs) and to processes for production thereof, to the use thereof for treatment and/or prophylaxis of disorders, and to the use thereof for production of medicaments for trea…
2011
The invention relates to selective estrogen receptor modulators (SERMs) and to processes for production thereof, to the use thereof for treatment and/or prophylaxis of disorders, and to the use thereof for production of medicaments for trea…
2011
The invention relates to selective estrogen receptor modulators (SERMs) and to processes for production thereof, to the use thereof for treatment and/or prophylaxis of disorders, and to the use thereof for production of medicaments for trea…
2011
The invention relates to selective estrogen receptor modulators (SERMs) and to processes for production thereof, to the use thereof for treatment and/or prophylaxis of disorders, and to the use thereof for production of medicaments for trea…
2011
The invention relates to selective estrogen receptor modulators (SERMs) and to processes for production thereof, to the use thereof for treatment and/or prophylaxis of disorders, and to the use thereof for production of medicaments for trea…
2011
The invention relates to selective estrogen receptor modulators (SERMs) and to processes for production thereof, to the use thereof for treatment and/or prophylaxis of disorders, and to the use thereof for production of medicaments for trea…
2009
VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridinamides, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis, as well as intermediate products for the production of the c…
2009
VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridinamides, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis, as well as intermediate products for the production of the c…
2009
VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridinamides, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis, as well as intermediate products for the production of the c…
2009
VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridinamides, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis, as well as intermediate products for the production of the c…
2009
VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridinamides, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis, as well as intermediate products for the production of the c…
2009
VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridinamides, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis, as well as intermediate products for the production of the c…
2009
VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridinamides, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis, as well as intermediate products for the production of the c…
2009
VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridinamides, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis, as well as intermediate products for the production of the c…
2009
VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridinamides, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis, as well as intermediate products for the production of the c…
2009
VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridinamides, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis, as well as intermediate products for the production of the c…
2009
VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridinamides, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis, as well as intermediate products for the production of the c…
2009
VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridinamides, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis, as well as intermediate products for the production of the c…